UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs

PLoS medicine, 2017-10, Vol.14 (10), p.e1002397-e1002397

2017

Volltextzugriff (PDF)

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia

Journal of managed care & specialty pharmacy, 2018-07, Vol.24 (7), p.632-642

2018

Volltextzugriff (PDF)

Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations

BMJ open respiratory research, 2024-07, Vol.11 (1), p.e002033

2024

Volltextzugriff (PDF)

A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted

PloS one, 2016-12, Vol.11 (12), p.e0168512-e0168512

2016

Volltextzugriff (PDF)

The Changing Face of the Cost-Utility Literature, 1990–2012

Value in health, 2015-03, Vol.18 (2), p.271-277

2015

Volltextzugriff (PDF)

Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process

Health Affairs, 2017-08, Vol.36 (8), p.1408-1415

2017

Volltextzugriff (PDF)

Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review

Journal of clinical medicine, 2021-04, Vol.10 (7), p.1527

2021

Volltextzugriff (PDF)

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia

Journal of managed care & specialty pharmacy, 2018-07, Vol.24 (7), p.632

2018

Volltextzugriff (PDF)

Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis

Thorax, 2024-09, Vol.79 (10), p.925-933

2024

Volltextzugriff (PDF)

Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis

Thorax, 2024-09, Vol.79 (10), p.915-924

2024

Volltextzugriff (PDF)

Private payers disagree with Medicare over medical device coverage about half the time

Health Affairs, 2015-08, Vol.34 (8), p.1376-1382

2015

Volltextzugriff (PDF)

Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis

The Journal of pediatrics, 2019-12, Vol.215, p.164-171.e2

2019

Volltextzugriff (PDF)

Healthcare resource utilization and costs among children with cystic fibrosis in the United States

Pediatric pulmonology, 2021-09, Vol.56 (9), p.2833-2844

2021

Volltextzugriff (PDF)

VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non–G551D-CFTR gating mutations

Journal of cystic fibrosis, 2023-01, Vol.22 (1), p.124-131

2023

Volltextzugriff (PDF)

Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs

Health Affairs, 2014-10, Vol.33 (10), p.1751-1760

2014

Volltextzugriff (PDF)

Patient Variability Seldom Assessed in Cost-effectiveness Studies

Medical decision making, 2018-05, Vol.38 (4), p.487-494

2018

Volltextzugriff (PDF)

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States

Pulmonary therapy, 2021-06, Vol.7 (1), p.281-293

2021

Volltextzugriff (PDF)

A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis

Pulmonary therapy, 2024-09

2024

Volltextzugriff (PDF)

The lag from FDA approval to published cost-utility evidence

Expert review of pharmacoeconomics & outcomes research, 2015-06, Vol.15 (3), p.399-402

2015

Volltextzugriff (PDF)

The State of Cost-Utility Analyses in Asia: A Systematic Review

Value in health regional issues, 2015-05, Vol.6, p.7-13

2015

Volltextzugriff (PDF)

Skills of the Trade: The Tufts Cost-Effectiveness Analysis Registry

Journal of benefit-cost analysis, 2012-01, Vol.3 (1), p.1-9

2012

Volltextzugriff (PDF)

Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval

Applied health economics and health policy, 2017-04, Vol.15 (2), p.227-235

2017

Volltextzugriff (PDF)

Skills of the Trade: The Tufts Cost-Effectiveness Analysis Registry

Journal of benefit-cost analysis, 2012, Vol.3 (5)

2012

Volltextzugriff (PDF)

HOSPITAL HEALTH CARE RESOURCE UTILIZATION (HCRU) BY PEOPLE WITH CYSTIC FIBROSIS (CF) IN BRAZIL: A CROSS-SECTIONAL STUDY USING DATA FROM THE PUBLIC HEALTHCARE SYSTEM

Brasília Médica, 2023, Vol.60

2023

Volltextzugriff (PDF)

The lag from FDA approval to published cost-utility evidence

Expert Review of Pharmacoeconomics & Outcomes Research, 2015, Vol.15 (3), p.399-402

2015

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(15)

Publikationsform

Sprache

Englisch
(26)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

When cost-effective interventions are unaffordable: Integrating cost-effectiveness and budget impact in priority setting for global health programs

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia

Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations

A Systematic Review of Cost-Effectiveness Studies Reporting Cost-per-DALY Averted

The Changing Face of the Cost-Utility Literature, 1990–2012

Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process

Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia

Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis

Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis

Private payers disagree with Medicare over medical device coverage about half the time

Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis

Healthcare resource utilization and costs among children with cystic fibrosis in the United States

VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non–G551D-CFTR gating mutations

Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs

Patient Variability Seldom Assessed in Cost-effectiveness Studies

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States

A Retrospective, Longitudinal Registry Study on the Long-Term Durability of Ivacaftor Treatment in People with Cystic Fibrosis

The lag from FDA approval to published cost-utility evidence

The State of Cost-Utility Analyses in Asia: A Systematic Review

Skills of the Trade: The Tufts Cost-Effectiveness Analysis Registry

Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval

Skills of the Trade: The Tufts Cost-Effectiveness Analysis Registry

HOSPITAL HEALTH CARE RESOURCE UTILIZATION (HCRU) BY PEOPLE WITH CYSTIC FIBROSIS (CF) IN BRAZIL: A CROSS-SECTIONAL STUDY USING DATA FROM THE PUBLIC HEALTHCARE SYSTEM

The lag from FDA approval to published cost-utility evidence

Suchergebnisse filtern